[1] Zhai Y, Ren ZP, Zhang M, et al. Abdominal obesity and its attribution to all-cause mortality in the general population with 14 years follow-up: findings from Shanxi cohort in China. Biomed Environ Sci, 2020; 33, 227−37.
[2] Liang B, Tang WW, Zhang WQ, et al. Prevalence and associated factors of diabetes mellitus in a very elderly Chinese population: a cross-sectional study. Biomed Environ Sci, 2020; 33, 315−22.
[3] Kemps H, Krankel N, Dörr M, et al. Exercise training for patients with type 2 diabetes and cardiovascular disease: What to pursue and how to do it. A Position Paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol, 2019; 26, 709−27.
[4] Lopez-Jaramillo P, Lopez-Lopez J, Lopez-Lopez C, et al. The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice. Diabetol Metab Syndr, 2014; 6, 31. doi:  10.1186/1758-5996-6-31
[5] Chinese Medical Association Diabetes Society. Guidelines for the prevention and treatment of type 2 diabetes mellitus in China (2013 vertion). Chin J Diabetes, 2014; 22, 2−42. (In Chinese
[6] Messerli FH, Grossman E. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension, 2001; 38, E11.
[7] Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull, 1994; 50, 272−98. doi:  10.1093/oxfordjournals.bmb.a072892
[8] Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med, 2010; 362, 1575−85. doi:  10.1056/NEJMoa1001286
[9] Vaccaro O, Stamler J, Neaton JD. Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epidemiol, 1998; 27, 636−41. doi:  10.1093/ije/27.4.636
[10] UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ, 1998; 317, 703−13.
[11] Taves MD, Ashwell JD. Glucocorticoids in T cell development, differentiation and function. Nat Rev Immunol, 2021; 21, 233−43. doi:  10.1038/s41577-020-00464-0
[12] Park SR, Kim SK, Kim SR, et al. Noncanonical functions of glucocorticoids: a novel role for glucocorticoids in performing multiple beneficial functions in endometrial stem cells. Cell Death Dis, 2021; 12, 612. doi:  10.1038/s41419-021-03893-4
[13] Seppä S, Tenhola S, Voutilainen R. Association of serum total osteocalcin concentrations with endogenous glucocorticoids and insulin sensitivity markers in 12-year-old children: a cross-sectional study. Front Endocrinol, 2019; 10, 798. doi:  10.3389/fendo.2019.00798
[14] Wallerius S, Rosmond R, Ljung T, et al. Rise in morning saliva cortisol is associated with abdominal obesity in men: a preliminary report. J Endocrinol Invest, 2003; 26, 616−9. doi:  10.1007/BF03347017
[15] Wang XH, Tian HM. Plasma levels of cortisol, free fatty acids and their relationships to insulin resistance in patients with type 2 diabetes. Chin J Endocrinol Metab, 2004; 20, 210−1. (In Chinese
[16] Grossmann C, Scholz T, Rochel M, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol, 2004; 151, 397−406. doi:  10.1530/eje.0.1510397
[17] Fardet L, Nazareth I, Petersen I. Synthetic glucocorticoids and early variations of blood pressure: a population-based cohort study. J Clin Endocrinol Metab, 2015; 100, 2777−83. doi:  10.1210/jc.2015-1127
[18] Shubin H. Long term (five or more years) administration of corticosteroids in pulmonary diseases. Dis Chest, 1965; 48, 287−90. doi:  10.1378/chest.48.3.287
[19] Covar RA, Leung DYM, McCormick D, et al. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol, 2000; 106, 651−9. doi:  10.1067/mai.2000.109830
[20] Glorioso N, Filigheddu F, Parpaglia PP, et al. 11 β-hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension. Eur Heart J, 2005; 26, 498−504. doi:  10.1093/eurheartj/ehi070
[21] Fukuda S, Yasu T, Kobayashi N, et al. Contribution of fluid shear response in leukocytes to hemodynamic resistance in the spontaneously hypertensive rat. Circ Res, 2004; 95, 100−8. doi:  10.1161/01.RES.0000133677.77465.38
[22] Schäfer SC, Wallerath T, Closs EI, et al. Dexamethasone suppresses eNOS and CAT-1 and induces oxidative stress in mouse resistance arterioles. Am J Physiol-Heart Circ Physiol, 2005; 288, H436−44. doi:  10.1152/ajpheart.00587.2004
[23] Yang SM, Zhang LB. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol, 2004; 2, 1−12. doi:  10.2174/1570161043476483
[24] Mildenhall LFJ, Battin MR, Morton SMB, et al. Exposure to repeat doses of antenatal glucocorticoids is associated with altered cardiovascular status after birth. Arch Dis Child Fetal Neonatal Ed, 2006; 91, F56−60.
[25] Liu XT, Mao ZX, Li YQ, et al. Cohort profile: the Henan rural cohort: a prospective study of chronic non-communicable diseases. Int J Epidemiol, 2019; 48, 1756−j. doi:  10.1093/ije/dyz039
[26] Liu X, Jiang JJ, Liu XT, et al. Association of serum testosterone with different classes of glucose metabolism and the mediation effect of obesity: the Henan Rural Cohort Study. Diabetes Metab Res Rev, 2019; 35, e3133.
[27] Xue Y, Yang KL, Wang BY, et al. Reproducibility and validity of an FFQ in the Henan Rural Cohort Study. Public Health Nutr, 2020; 23, 34−40. doi:  10.1017/S1368980019002416
[28] Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sport Exer, 2003; 35, 1381−95. doi:  10.1249/01.MSS.0000078924.61453.FB
[29] Tian ZY, Li YQ, Mao ZX, et al. Sex-specific relationship between visceral fat index and dyslipidemia in Chinese rural adults: the Henan Rural Cohort Study. Prev Med, 2018; 116, 104−11. doi:  10.1016/j.ypmed.2018.09.009
[30] Zhang HQ, Li YQ, Mao ZX, et al. A dose-response association of night sleep duration with hypertension in a Chinese rural population: the Henan Rural Cohort Study. J Am Soc Hypertens, 2018; 12, 867−79.e3. doi:  10.1016/j.jash.2018.10.005
[31] Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease the Framingham heart study. Circulation, 2009; 119, 243−50. doi:  10.1161/CIRCULATIONAHA.108.797936
[32] Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 2002; 360, 1903−13. doi:  10.1016/S0140-6736(02)11911-8
[33] Zhang HQ, Li YQ, Zhao XY, et al. The association between PSQI score and hypertension in a Chinese rural population: the Henan Rural Cohort Study. Sleep Med, 2019; 58, 27−34. doi:  10.1016/j.sleep.2019.03.001
[34] Yu D, Du ML, Sun DJ, et al. Characteristics of hypertension death in low-income regions of Inner Mongolia, China. Biomed Environ Sci, 2020; 33, 53−7.
[35] Adeniyi OV, Yogeswaran P, Longo-Mbenza B, et al. Uncontrolled hypertension and its determinants in patients with concomitant type 2 diabetes mellitus (T2DM) in rural South Africa. PLoS One, 2016; 11, e0150033. doi:  10.1371/journal.pone.0150033
[36] Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA, 2013; 310, 959−68. doi:  10.1001/jama.2013.184182
[37] Kotani M, Tamura N, Inoue T, et al. A case of type B insulin resistance syndrome treated with low-dose glucocorticoids. Endocrinol Diabetes Metab Case Rep, 2019; 2019, 19−0115.
[38] Liu YJ, Nakagawa Y, Wang Y, et al. Increased glucocorticoid receptor and 11 β-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice. Diabetes, 2005; 54, 32−40. doi:  10.2337/diabetes.54.1.32
[39] Cooper MS, Seibel MJ, Zhou H. Glucocorticoids, bone and energy metabolism. Bone, 2016; 82, 64−8. doi:  10.1016/j.bone.2015.05.038
[40] Brennan-Speranza TC, Henneicke H, Gasparini SJ, et al. Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest, 2012; 122, 4172−89. doi:  10.1172/JCI63377
[41] Kokkinopoulou I, Diakoumi A, Moutsatsou P. Glucocorticoid receptor signaling in diabetes. Int J Mol Sci, 2021; 22, 11173. doi:  10.3390/ijms222011173
[42] Björntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabet Med, 1999; 16, 373−83. doi:  10.1046/j.1464-5491.1999.00067.x
[43] Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. Pediatr Nephrol, 2012; 27, 1059−66. doi:  10.1007/s00467-011-1928-4
[44] Bertagna X, Bertagna C, Laudat MH, et al. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome. J Clin Endocrinol Metab, 1986; 63, 639−43. doi:  10.1210/jcem-63-3-639
[45] Kalimi M. Role of antiglucocorticoid RU 486 on dexamethasone-induced hypertension in rats. Am J Physiol Endocrinol Metab, 1989; 256, E682−5. doi:  10.1152/ajpendo.1989.256.5.E682
[46] Mangos GJ, Whitworth JA, Williamson PM, et al. Glucocorticoids and the kidney. Nephrology, 2003; 8, 267−73. doi:  10.1111/j.1440-1797.2003.00215.x
[47] Banerjee RR, Marina N, Katznelson L, et al. Mifepristone treatment of Cushing's syndrome in a pediatric patient. Pediatrics, 2015; 136, E1377−81. doi:  10.1542/peds.2015-0684
[48] Davies AO, Lefkowitz RJ. Regulation of β-adrenergic receptors by steroid hormones. Annu Rev Physiol, 1984; 46, 119−30. doi:  10.1146/annurev.ph.46.030184.001003
[49] Odore R, Badino P, Pagliasso S, et al. Changes in lymphocyte glucocorticoid and β-adrenergic receptors in veal calves treated with clenbuterol and steroid hormones for growth-promoting purposes. J Vet Pharmacol Ther, 2006; 29, 91−7. doi:  10.1111/j.1365-2885.2006.00719.x
[50] Whitworth JA, Brown MA, Kelly JJ, et al. Experimental studies on cortisol-induced hypertension in humans. J Hum Hypertens, 1995; 9, 395−9.
[51] Liang W. Variation in food quality may threaten the validity of epidemiological studies in China. J Epidemiol Community Health, 2006; 60, 1099. doi:  10.1136/jech.2006.049957
[52] Conn PHO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med, 1994; 236, 619−32. doi:  10.1111/j.1365-2796.1994.tb00855.x
[53] Baid S, Nieman LK. Glucocorticoid excess and hypertension. Curr Hypertens Rep, 2004; 6, 493−9. doi:  10.1007/s11906-004-0046-0
[54] Whitworth JA, Mangos GJ, Kelly JJ. Cushing, cortisol, and cardiovascular disease. Hypertension, 2000; 36, 912−6. doi:  10.1161/01.HYP.36.5.912
[55] Mir N, Chin SA, Riddell MC, et al. Genomic and non-genomic actions of glucocorticoids on adipose tissue lipid metabolism. Int J Mol Sci, 2021; 22, 8503. doi:  10.3390/ijms22168503
[56] Martocchia A, Curto M, Toussan L, et al. Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders. Recent Pat CNS Drug Discov, 2011; 6, 196−204.